Synektik (WAR:SNT) Other Stockholders Equity: zł-236.1 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:SNT Synektik SA WAR:SNT
90 GF Score
Price zł374.20
GF Value zł231.70
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Synektik Other Stockholders Equity?

Synektik WAR:SNT -3.06% 90 Other Stockholders Equity is zł-236.1 Mil as of Mar. 2026. GuruFocus rates WAR:SNT with a GF Score™ of 90/100 and a GF Value™ of zł231.70 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Synektik's Other Stockholders Equity for the quarter that ended in Mar. 2026 was zł-236.1 Mil.

Synektik's quarterly Other Stockholders Equity declined from Sep. 2025 (zł68.2 Mil) to Dec. 2025 (zł68.0 Mil) and declined from Dec. 2025 (zł68.0 Mil) to Mar. 2026 (zł-236.1 Mil).

Synektik's annual Other Stockholders Equity declined from Sep. 2023 (zł60.9 Mil) to Sep. 2024 (zł60.0 Mil) but then increased from Sep. 2024 (zł60.0 Mil) to Sep. 2025 (zł68.2 Mil).

Synektik Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Synektik's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Synektik Other Stockholders Equity Chart

Synektik Annual Data
Trend Dec15 Dec16 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 64.69 65.51 60.86 60.05 68.16

Synektik Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 67.04 67.49 68.16 67.99 -236.11
WAR:SNT
90GF Score
Synektik SA WAR:SNT
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Synektik Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of zł-236.1 Mil mean?
Synektik (WAR:SNT) has a Other Stockholders Equity of zł-236.1 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Synektik and its competitors.
Is Synektik's Other Stockholders Equity too high?
Synektik's current Other Stockholders Equity is zł-236.1 Mil. Overall, Synektik has a GF Score™ of 90/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Synektik's Other Stockholders Equity compare to ABT and SYK?
Synektik's Other Stockholders Equity of zł-236.1 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Medical Devices & Instruments company?
A good Other Stockholders Equity depends on the Medical Devices & Instruments industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Synektik and its competitors. Synektik's current Other Stockholders Equity is zł-236.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synektik stock overvalued right now?
Based on GuruFocus' analysis, Synektik (WAR:SNT) is currently considered Significantly Overvalued. The stock's GF Value™ is zł231.70, compared to a current price of zł374.20 — trading 61.5% above its estimated fair value. The current Other Stockholders Equity is zł-236.1 Mil. Synektik's overall GF Score™ is 90/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Synektik (WAR:SNT), the current Other Stockholders Equity is zł-236.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Synektik (WAR:SNT) Overvalued in 2026?

Based on GuruFocus' analysis, Synektik stock appears to be overvalued. The current stock price of zł374.20 is trading 61.5% above its estimated GF Value™ of zł231.70. GuruFocus considers Synektik to be Significantly Overvalued.

Key valuation signals for WAR:SNT:

  • Other Stockholders Equity: zł-236.1 Mil
  • GF Value™: zł231.70 vs. price of zł374.20 (61.5% above fair value)
  • GF Score™: 90/100 with 7 warning signs

No single metric tells the full story. See the WAR:SNT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Synektik Business Description

Other Exchanges A2P:Germany
Address Aleja Wincentego Witosa 31, Warsaw, POL, 00-710
Synektik SA is a supplier of innovative products, services and IT solutions for diagnostic imaging and nuclear medicine. It sells medical devices and IT solutions used in radiology and operates research laboratory for diagnostic imaging systems and a service centre for medical equipment. Its operating segments include the sale of medical equipment used in radiology and nuclear medicine and IT solutions, Maintenance services for medical equipment as well as acceptance and specialist tests and Radiopharmaceutical production.
90GF Score

Get the complete analysis for WAR:SNT

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł374.20
Price
zł231.70
GF Value